Amyotrophic Lateral Sclerosis Treatment Market Analysis
%20Treatment%20Market.jpg "Amyotrophic Lateral Sclerosis (ALS) Treatment Market")
Amyotrophic Lateral Sclerosis Treatment Market
Another name for Amyotrophic Lateral Sclerosis is Lou
Gehrig's disease (ALS). It is a degenerative neurological disease in which the
nerve cells in the nervous system that regulate voluntary muscles are damaged.
The condition is frequently characterised by the twitching, stiffness, and
weakening of the arms and hands due to muscle loss. The most common kind of
motor neuron disease is ALS, which impairs the ability of the brain to control
voluntary movements by causing the body's cells to degenerate and die.
In nearly half of ALS cases, patients lose their ability to
swallow, inhale, communicate, move, and use their hands. The National Institute
of Neurological Disorders and Stroke reports that within three to five years of
progressive paralysis, persons with ALS frequently pass away from respiratory
failure (NINDS).
The sporadic kind of Amyotrophic
Lateral Sclerosis (ALS) Treatment Market, which accounts for
90–95 percent of all cases in the United States, is also mentioned, along with
the fact that the familial type accounts for the remaining cases. Each
offspring of a person with familial ALS (FALS) has a 50% chance of inheriting
the genetic mutation and developing the illness. 25–40% of those with familial
ALS often have the C9ORF72 gene defect. A mutation in this gene results in
frontotemporal dementia (FTD), a condition that can coexist with ALS and be
referred to as ALS-FTD. The damage caused by amyotrophic lateral sclerosis
cannot be repaired, however treatments can slow the progression of symptoms.
Comments
Post a Comment